Referenser ASH-rapport

1. Statistics adapted from the American Cancer Society's publication, Cancer Facts and Figures 2007, page 4.

2. Socialstyrelsen, Epidemiologiskt centrum. Cancer Incidence in Sweden
2006, page 46.

3. Favorable long-term follow-up results over six years for Response, survival and safety with imatinib mesylate therapy in Chronic phase chronic myeloid leukemia post failure of interferonalpha Treatment, Hochhaus et al. 0 (2007): blood-2007-07-103523v1. (2007)

4. Bray D, Johnson A, et al. Essential Cell Biology:An Introduction to the Molecular Biology of the Cell. New York: Garland; 1998.

5. Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: Bye he GIMEMAWorking Party on Chronic Myeloid Leukemia.
6. Lahaye t, Riehm B, Berger U et al. Cancer  2005;103: 1659-1669
7. Donato NJ, et al. Blood 2003;101:690–698; 2Weisberg E, Griffen JD. Blood 2000; 95:3498–3505; 3Mahon FX, et al. Blood 2003; 101:2368–2373 4Branford S, et al. Blood 2003;102:276–283.
8. Quintas et al  Nature Reviews Drug Discovery 2007.
9. ASH-abstract number [25] IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Oral Session Abstract #25 appears in Blood, Volume 110, issue 11, November 16, 2007
10.  Deininger MWN, Goldman JM, Melo JV. Blood ;96:3343-3352

11.  Produktresumé november 2007 (SPRYCEL™ (dasatinib) Summary of Product  Characteristics, Nov 2007)

12. Talpaz M, Shah NP, Kantarijian H, et al. N Engl J Med. 2006;354:2531-2541

13. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukaemia. Blood, Dec 2007; doi:10.1182/blood-2007-04-083196

14. ASH-abstract number [733] Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML). Session Type: Oral Session Authors: J. Cortes, T. Bruemmendorf, H. Kantarjian, J. Khoury, G. Rosti, T. Fischer, L. Tornaghi, B. Hewes, E.C. Martin, C. Gambacorti-Passerini (Intr. by Jorge Cortes).
15. ASH-abstract number [470] Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005). Abstract #470 appears in Blood, Volume 110, issue 11, November 16, 2007
16. ASH-abstract number [472] Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the START Program. Abstract #472 appears in Blood, Volume 110, issue 11, November 16, 2007
17. ASH-abstract number [734] Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013). Abstract #734 appears in Blood, Volume 110, issue 11, November 16, 2007
18. ASH-abstract number [736] Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017). Abstract #736 appears in Blood, Volume 110, issue 11, November 16, 2007